Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). Sofpironium bromide is an anticholinergic agent that is applied to the skin.
It was approved for medical use in Japan in 2020, and in the United States in June 2024.
Medical uses
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.
Mechanism of action
The pharmacodynamics of sofpironium bromide are unknown.
Society and culture
Legal status
It was approved for medical use in Japan in November 2020, and in the United States in June 2024.
Brand names
Sofpironium bromide is the international nonproprietary name.
It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.
References
Further reading
- Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, et al. (March 2021). "A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis". The Journal of Dermatology. 48 (3): 279–288. doi:10.1111/1346-8138.15668. PMC 7986147. PMID 33410265.
External links
- "Sofpironium Bromide (Code C152384)". NCI Thesaurus.
- Clinical trial number NCT03836287 for "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (CardiganI)" at ClinicalTrials.gov
- Clinical trial number NCT03948646 for "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (CARDIGANII)" at ClinicalTrials.gov
